Technical Analysis for CTNM - Contineum Therapeutics, Inc.

Grade Last Price % Change Price Change
C 15.50 3.61% 0.54
CTNM closed up 3.61 percent on Friday, May 17, 2024, on 80 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Morning Star Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
20 DMA Resistance Bearish 3.61%
Down 3 Days in a Row Weakness 3.61%
Down 4 Days in a Row Weakness 3.61%
Down 5 Days in a Row Weakness 3.61%
20 DMA Resistance Bearish 1.24%
Gapped Up Strength 1.24%

   Recent Intraday Alerts

Alert Time
Rose Above 10 DMA 1 day ago
Up 3% 1 day ago
Fell Below Previous Day's Low 1 day ago
Down 1% 1 day ago
Up 2% 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Contineum Therapeutics, Inc. Description

Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that the Company believes, once modulated, can demonstrably impact the course of disease. The Company has a pipeline of internally-developed programs to address multiple NI&I disorders, including PIPE-791, an LPA1 receptor antagonist, in Phase 1 clinical trials for idiopathic pulmonary fibrosis and progressive multiple sclerosis, and PIPE-307, a selective inhibitor of the M1 receptor in a Phase 2 clinical trial for relapse-remitting multiple sclerosis. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Neuroscience Inflammation Multiple Sclerosis Idiopathic Pulmonary Fibrosis Small Molecule Therapies

Is CTNM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.08
52 Week Low 13.27
Average Volume 78,852
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 15.46
10-Day Moving Average 15.39
Average True Range 0.92
RSI (14) 51.22
ADX 36.45
+DI 8.14
-DI 21.08
Chandelier Exit (Long, 3 ATRs) 13.32
Chandelier Exit (Short, 3 ATRs) 16.03
Upper Bollinger Bands 16.45
Lower Bollinger Band 14.46
Percent B (%b) 0.52
BandWidth 12.87
MACD Line -0.03
MACD Signal Line -0.03
MACD Histogram -0.0015
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.87
Resistance 3 (R3) 16.77 16.21 16.64
Resistance 2 (R2) 16.21 15.87 16.26 16.56
Resistance 1 (R1) 15.86 15.65 16.04 15.96 16.49
Pivot Point 15.30 15.30 15.39 15.35 15.30
Support 1 (S1) 14.95 14.96 15.13 15.05 14.51
Support 2 (S2) 14.39 14.74 14.44 14.44
Support 3 (S3) 14.04 14.39 14.36
Support 4 (S4) 14.14